JPRN-jRCTs071210124招募中4 期
Efficacy and safety of once-daily single-Inhaler TRiple (Trelegy Ellipta) therApy for Japanese with mild to moderate COPD in Kyushu (TRACK study)
Hiromasa Inoue0 个研究点目标入组 668 人开始时间: 2022年2月2日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 668
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.40 years old and over
- •2.Mild to moderate COPD
- •3.Impairments of QOL (>=7 points of total COPD assessment test [CAT] score).
- •4.Airflow obstruction <0.7 of an FEV1/FVC ratio and %FEV1 predicted >50% assessed by Japanese Respiratory Society (JRS) criteria [32, 33] after administration of short-acting beta2 agonist (SABA).
- •5.Patients without a history of severe exacerbations in the last 12 months.
- •6.Prescription of LAMA or LABA alone monotherapy, or treatment naive
- •Gender and smoking history do not matter. Non-smokers, passive smokers, former smokers and current smokers can all be registered.
排除标准
- •1.Women of childbearing potential. This includes women who are pregnant or lactating or are planning on becoming pregnant during the study.
- •2.Patients with a current diagnosis of asthma. (However, those patients with a prior history of asthma are eligible if they have a current diagnosis of COPD, and patients with ACO-like features, namely those whose condition will be partially met to the conditions defined for ACO in JRS guidance, may be included.)
- •3.Patients who cannot perform lung function tests
- •4.Patients who had acute respiratory tract infection (e.g. pneumonia) or moderate/severe COPD exacerbation within 4 weeks at the screening
- •5.Severe or unstable other comorbid diseases
- •6.Active respiratory infections or malignancies
- •7.Other chronic respiratory diseases (bronchiectasis, interstitial pneumonias, pneumoconiosis)
- •8.Patients who cannot use any inhalation devices
- •9.Past history of severe side effects or history of allergy/hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator contraindicates study participation.(Contraindications to the use of each drug follow the package inserts.)
- •10. Patients taking any investigational drug/ clinical study drug treatment within 30 days prior to Visit 1(Screening).
- •11.Patients who are recognized as inappropriate subjects in the study by physicians (eg, dementia, psychological disorders, cerebrovascular diseases with palsy, etc), because we will get informed consents by patients themselves and will not set other gardiners or proxies for informed consents.
- •12. Patients who are judged to be inappropriate by the investigator or sub-investigator based on the package insert of the target drugs.
研究者
相似试验
招募中
不适用
Efficacy and safety of once-daily single-Inhaler TRiple(Trelegy Ellipta) therApy for Japanese with mild to moderate COPD in KyushuChronic obstructive pulmonary disease (COPD)JPRN-UMIN000046812Kagoshima university668
招募中
不适用
The Real World Effectiveness of Single Inhaler Triple Treatment through Assorted Respiratory Outcomes when Switched from Multiple Inhaler Triple Therapies (RESTART study)KCT0007752Gyeongsang National University Hospital107
尚未招募
不适用
sefulluness of single inhalaer treatment with long acting muscarinic antagonist, long acting beta agosit, and inhaled corticosteroid in symptomatic patients with chronic obstructive pulmonary disease without asthma and exacerbatioChronic obstructive pulmonary diseaseJPRN-UMIN000039915Hamamatsu Rosai Hospital15
尚未招募
4 期
Comparison of safety of transdermal ketoprofen and diclofenac patches in post-operative pain managementCTRI/2024/01/061659Sri Lalithambigai medical college
招募中
3 期
Comparison of Inhaled Tocilizumab with Intravenous Tocilizumab in hospitalized patients with COVID-19IRCT20151227025726N27Shahid Beheshti University of Medical Sciences100